About
Biosimilars
Areas of Focus
Categories
BiosimilarsSan Diego & Southern California
Team (6)
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
7
As Collaborator
0
Total Enrollment
1,184
By Phase
PHASE3: 1PHASE1: 5PHASE1/PHASE2: 1
By Status
ACTIVE_NOT_RECRUITING: 3RECRUITING: 2UNKNOWN: 2
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06206733Lead Sponsor
ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma
PHASE3Recruiting
780 participants
Started: Jan 25, 2024 · Completed: Dec 30, 2028
NCT05940428Lead Sponsor
A Study of ASKG712 in Patients With Diabetic Macular Edema
PHASE1Active, not recruiting
26 participants
Started: Oct 23, 2023 · Completed: Dec 31, 2025
NCT05509985Lead Sponsor
A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors
PHASE1Unknown
100 participants
Started: Aug 9, 2023 · Completed: Sep 9, 2024
NCT05867420Lead Sponsor
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
PHASE1Recruiting
104 participants
Started: Aug 3, 2023 · Completed: Dec 31, 2025
NCT05632939Lead Sponsor
ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.
PHASE1/PHASE2Active, not recruiting
62 participants
Started: Feb 21, 2023 · Completed: Feb 10, 2026
Locations (1)
Headquarters
Camarillo, CA, United States
Map
Loading map...